Lerapolturev is under clinical development by Istari Oncology and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lerapolturev’s likelihood of approval (LoA) and phase transition for Bladder Cancer took place on 13 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 13 Jul 2022 decreased Lerapolturev’s Phase Transition Success Rate (PTSR) for Muscle Invasive Bladder Cancer (MIBC).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lerapolturev Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lerapolturev overview

Lerapolturev is under development for the treatment of recurrent glioblastoma (recurrent grade IV glioma), supratentorial glioma, melanoma and triple negative breast cancer, hormone positive breast cancer, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma, medulloblastoma, or atypical teratoid/rhabdoid tumor, bladder cancer, muscle invasive bladder cancer, urothelial carcinoma, HER2+ breast cancer, gastric, esophageal, and non-muscle invasive bladder cancer. The vaccine comprises of live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. The vaccine is administered through intra-tumoral, intravesical and intralesional route. It was also under development for head and neck cancer squamous cell carcinoma, oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer.

Istari Oncology overview

Istari Oncology, Inc., a biotechnology company that focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma. The company is headquartered in United States.

Quick View Lerapolturev LOA Data

Report Segments
  • Innovator
Drug Name
  • Lerapolturev
Administration Pathway
  • Intralesional
  • Intratumor
  • Intravesical
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.